MSN Group is the fastest growing research-based pharmaceutical company based out of India. The group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals to make them more accessible.
Private/Public:private
Phone:+91 40 30438600
Fax:+91 40 30438638
Website:http://www.msnlabs.com/index.html
Address:MSN House, Plot No: C-24,
Industrial Estate, Sanathnagar,
Hyderabad - 18 Telangana, India
2003
Since
6000
Employees
1
Country
6
Top Service Categories
127
Sub-Service Categories
Top Services
Product Groups
For Services/Products
API/Biologicals Production
API/Biologics development and manufacturing
Reagents/excipients manufactured
Package and Label
Specific Services - Packaging etc.
Formulation
Formulation development related
Formulation types
Manufacturing Equipment
Preformulation
Preformulation Services
India
- (19.Apr.2022) Breckenridge Pharmaceutical, Inc. Announces Launch of Lacosamide Tablets, USP (Generic Version of Vimpat) Manufactured by MSN Laboratories Private Limited
- (14.Jan.2022) Vanda Pharmaceuticals Settles HETLIOZ Patent Litigation With MSN
- (06.Jan.2022) MSN Group is All Set to Launch MOLULOW 200 Mg Capsules, Generic of Molnupiravir, for Treatment of Covid-19 in India
- (22.Dec.2021) Novadoz Pharmaceuticals' Corporate Group Entity, MSN Pharmaceuticals Inc., Has Received USFDA Clearance for Its State-of-the-Art Manufacturing Facility in Piscataway, NJ
- (21.Dec.2021) MSN Pharmaceuticals Inc. Successfully Completed Its Maiden USFDA Audit with Zero Observations
- (17.Dec.2021) MSN's Generic Drug Gets USFDA's Tentative Nod
- (17.Nov.2021) MSN Labs Launches Generic Drug to Treat Epilepsy in Infants
- (01.Oct.2021) MSN Labs Launches Generic Cangrelor as Adjunct to Coronary Angioplasty
- (23.Sep.2021) MSN Labs Launches Branded Generic of Cabozantinib for Treatment of Renal Cell Carcinoma
- (09.Jul.2021) MSN Labs Enters into Licence Agreement with DRDO for 2-DG